{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:56:47Z","timestamp":1780372607675,"version":"3.54.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":1789,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T00:00:00Z","timestamp":1611619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bj\u00f8rknes University College"},{"name":"K.G. Jebsen Center for Heart Failure Research"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Sacubitril\/valsartan (sac\/val) has shown superior effect compared with blockade of the renin\u2013angiotensin\u2013aldosterone system in heart failure with reduced ejection fraction. We aimed to investigate effects of sac\/val compared with valsartan in a pressure overload model of heart failure with preserved ejection fraction (HFpEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Sprague\u2013Dawley rats underwent aortic banding or sham (n = 16) surgery and were randomized to sac\/val (n = 28), valsartan (n = 29), or vehicle (n = 26) treatment for 8 weeks. Sac\/val reduced left ventricular weight by 11% compared with vehicle (P = 0.01) and 9% compared with valsartan alone (P = 0.04). Only valsartan reduced blood pressure compared with sham (P = 0.02). Longitudinal early diastolic strain rate was preserved in sac\/val compared with sham, while it was reduced by 23% in vehicle (P = 0.03) and 24% in valsartan (P = 0.02). Diastolic dysfunction, measured by E\/e'SR, increased by 68% in vehicle (P &amp;lt; 0.01) and 80% in valsartan alone (P &amp;lt; 0.001), while sac\/val showed no increase. Neither sac\/val nor valsartan prevented interstitial fibrosis. Although ejection fraction was preserved, we observed mild systolic dysfunction, with vehicle showing a 28% decrease in longitudinal strain (P &amp;lt; 0.01). Neither sac\/val nor valsartan treatment improved this dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a model of HFpEF induced by cardiac pressure overload, sac\/val reduced hypertrophy compared with valsartan alone and ameliorated diastolic dysfunction. These effects were independent of blood pressure. Early systolic dysfunction was not affected, supporting the notion that sac\/val has the largest potential in conditions characterized by reduced ejection fraction. Observed anti-hypertrophic effects in preserved ejection fraction implicate potential benefit of sac\/val in the clinical setting of hypertrophic remodelling and impaired diastolic function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13177","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T15:39:36Z","timestamp":1611675576000},"page":"918-927","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Sacubitril\/Valsartan Ameliorates Cardiac Hypertrophy and Preserves Diastolic Function in Cardiac Pressure Overload"],"prefix":"10.1093","volume":"8","author":[{"given":"Einar Sjaastad","family":"Nord\u00e9n","sequence":"first","affiliation":[{"name":"Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo , Oslo ,","place":["Norway"]},{"name":"Department for Health Sciences, Bj\u00f8rknes University College , Oslo ,","place":["Norway"]},{"name":"KG Jebsen Center for Cardiac Research, University of Oslo , Oslo ,","place":["Norway"]},{"name":"Center for Heart Failure Research, Oslo University Hospital , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e5rd Andre","family":"Bendiksen","sequence":"additional","affiliation":[{"name":"Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo , Oslo ,","place":["Norway"]},{"name":"Department for Health Sciences, Bj\u00f8rknes University College , Oslo ,","place":["Norway"]},{"name":"KG Jebsen Center for Cardiac Research, University of Oslo , Oslo ,","place":["Norway"]},{"name":"Center for Heart Failure Research, Oslo University Hospital , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Andresen","sequence":"additional","affiliation":[{"name":"Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaja Knudsen","family":"Bergo","sequence":"additional","affiliation":[{"name":"Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo , Oslo ,","place":["Norway"]},{"name":"KG Jebsen Center for Cardiac Research, University of Oslo , Oslo ,","place":["Norway"]},{"name":"Center for Heart Failure Research, Oslo University Hospital , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil Knut","family":"Espe","sequence":"additional","affiliation":[{"name":"Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo , Oslo ,","place":["Norway"]},{"name":"Department for Health Sciences, Bj\u00f8rknes University College , Oslo ,","place":["Norway"]},{"name":"KG Jebsen Center for Cardiac Research, University of Oslo , Oslo ,","place":["Norway"]},{"name":"Center for Heart Failure Research, Oslo University Hospital , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almira","family":"Hasic","sequence":"additional","affiliation":[{"name":"Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo , Oslo ,","place":["Norway"]},{"name":"KG Jebsen Center for Cardiac Research, University of Oslo , Oslo ,","place":["Norway"]},{"name":"Center for Heart Failure Research, Oslo University Hospital , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida Marie","family":"Hauge-Iversen","sequence":"additional","affiliation":[{"name":"Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo , Oslo ,","place":["Norway"]},{"name":"KG Jebsen Center for Cardiac Research, University of Oslo , Oslo ,","place":["Norway"]},{"name":"Center for Heart Failure Research, Oslo University Hospital , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanni","family":"Veras","sequence":"additional","affiliation":[{"name":"Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo , Oslo ,","place":["Norway"]},{"name":"KG Jebsen Center for Cardiac Research, University of Oslo , Oslo ,","place":["Norway"]},{"name":"Center for Heart Failure Research, Oslo University Hospital , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwan I.","family":"Hussain","sequence":"additional","affiliation":[{"name":"Novartis AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivar","family":"Sjaastad","sequence":"additional","affiliation":[{"name":"Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo , Oslo ,","place":["Norway"]},{"name":"Department for Health Sciences, Bj\u00f8rknes University College , Oslo ,","place":["Norway"]},{"name":"KG Jebsen Center for Cardiac Research, University of Oslo , Oslo ,","place":["Norway"]},{"name":"Center for Heart Failure Research, Oslo University Hospital , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geir","family":"Christensen","sequence":"additional","affiliation":[{"name":"Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo , Oslo ,","place":["Norway"]},{"name":"KG Jebsen Center for Cardiac Research, University of Oslo , Oslo ,","place":["Norway"]},{"name":"Center for Heart Failure Research, Oslo University Hospital , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cataliotti","sequence":"additional","affiliation":[{"name":"Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo , Oslo ,","place":["Norway"]},{"name":"KG Jebsen Center for Cardiac Research, University of Oslo , Oslo ,","place":["Norway"]},{"name":"Center for Heart Failure Research, Oslo University Hospital , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,26]]},"reference":[{"key":"2026012115083064800_ehf213177-bib-0001","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115083064800_ehf213177-bib-0002","volume-title":"FDA approves new drug to treat heart failure","author":"Administration USFaD"},{"key":"2026012115083064800_ehf213177-bib-0003","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012115083064800_ehf213177-bib-0004","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012115083064800_ehf213177-bib-0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2010.165","article-title":"Epidemiology and risk profile of heart failure","volume":"8","author":"Bui","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"2026012115083064800_ehf213177-bib-0006","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.007451","article-title":"Progression of hypertrophy and myocardial fibrosis in aortic stenosis","volume":"11","author":"Everett","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026012115083064800_ehf213177-bib-0007","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1524-6175.2007.06626.x","article-title":"Mechanisms of cardiac fibrosis in hypertension","volume":"9","author":"Diez","year":"2007","journal-title":"J Clin Hyp"},{"key":"2026012115083064800_ehf213177-bib-0008","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40292-017-0196-1","article-title":"Cardiac natriuretic peptides, hypertension and cardiovascular risk","volume":"24","author":"Sarzani","year":"2017","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"2026012115083064800_ehf213177-bib-0009","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1161\/CIRCHEARTFAILURE.114.001785","article-title":"Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy","volume":"8","author":"von Lueder","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2026012115083064800_ehf213177-bib-0010","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005565","article-title":"Sacubitril\/valsartan decreases cardiac fibrosis in left ventricle pressure overload by restoring PKG signaling in cardiac fibroblasts","volume":"12","author":"Burke","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2026012115083064800_ehf213177-bib-0011","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.cardfail.2018.10.006","article-title":"A novel paradigm for sacubitril\/valsartan: beta-endorphin elevation as a contributor to exercise tolerance improvement in rats with preexisting heart failure induced by pressure overload","volume":"24","author":"Maslov","year":"2018","journal-title":"J Card Fail"},{"key":"2026012115083064800_ehf213177-bib-0012","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/10976640600723664","article-title":"How to perform an accurate assessment of cardiac function in mice using high-resolution magnetic resonance imaging","volume":"8","author":"Schneider","year":"2006","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026012115083064800_ehf213177-bib-0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2342-10-1","article-title":"Design and validation of Segment\u2014freely available software for cardiovascular image analysis","volume":"10","author":"Heiberg","year":"2010","journal-title":"BMC Med Imaging"},{"key":"2026012115083064800_ehf213177-bib-0014","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1532-429X-15-82","article-title":"Novel insight into the detailed myocardial motion and deformation of the rodent heart using high-resolution phase contrast cardiovascular magnetic resonance","volume":"15","author":"Espe","year":"2013","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026012115083064800_ehf213177-bib-0015","first-page":"H143","article-title":"Regional right ventricular function in rats: a novel magnetic resonance imaging method for measurement of right ventricular strain","volume":"318","author":"Espe","year":"2020","journal-title":"Am J Physiol: Heart Circ Phys Ther"},{"key":"2026012115083064800_ehf213177-bib-0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165079","article-title":"The heparan sulfate proteoglycan glypican-6 is upregulated in the failing heart, and regulates cardiomyocyte growth through ERK1\/2 signaling","volume":"11","author":"Melleby","year":"2016","journal-title":"PLoS ONE"},{"key":"2026012115083064800_ehf213177-bib-0017","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ejhf.799","article-title":"Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides","volume":"19","author":"D'Elia","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115083064800_ehf213177-bib-0018","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ejhf.76","article-title":"Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial","volume":"16","author":"Jhund","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026012115083064800_ehf213177-bib-0019","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/eurheartj\/ehw570","article-title":"Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF","volume":"38","author":"Bohm","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012115083064800_ehf213177-bib-0020","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1073\/pnas.051625598","article-title":"A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy","volume":"98","author":"Kishimoto","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026012115083064800_ehf213177-bib-0021","first-page":"743","article-title":"Global strain rate imaging for the estimation of diastolic function in HFNEF compared with pressure\u2013volume loop analysis","volume":"11","author":"Kasner","year":"2010","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012115083064800_ehf213177-bib-0022","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/eurheartj\/eht179","article-title":"Early diastolic strain rate in relation to systolic and diastolic function and prognosis in acute myocardial infarction: a two-dimensional speckle-tracking study","volume":"35","author":"Ersboll","year":"2014","journal-title":"Eur Heart J"},{"key":"2026012115083064800_ehf213177-bib-0023","first-page":"H289","article-title":"Synergy between sacubitril and valsartan leads to hemodynamic, antifibrotic, and exercise tolerance benefits in rats with preexisting heart failure","volume":"316","author":"Maslov","year":"2019","journal-title":"Am J Physiol: Heart Circ Phys Ther"},{"key":"2026012115083064800_ehf213177-bib-0024","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1161\/CIRCHEARTFAILURE.113.000825","article-title":"Mechanisms of diastolic dysfunction in heart failure with a preserved ejection fraction: if it's not one thing it's another","volume":"6","author":"LeWinter","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026012115083064800_ehf213177-bib-0025","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0002-9149(01)01893-8","article-title":"Effects of therapeutic doses of human atrial natriuretic peptide on load and myocardial performance in patients with congestive heart failure","volume":"88","author":"Mizuno","year":"2001","journal-title":"Am J Cardiol"},{"key":"2026012115083064800_ehf213177-bib-0026","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jacc.2013.09.052","article-title":"Impaired systolic function by strain imaging in heart failure with preserved ejection fraction","volume":"63","author":"Kraigher-Krainer","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026012115083064800_ehf213177-bib-0027","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1161\/CIRCULATIONAHA.115.015884","article-title":"Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone","volume":"132","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"2026012115083064800_ehf213177-bib-0028","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.113.02149","article-title":"Left ventricular strain and transmural distribution of structural remodeling in hypertensive heart disease","volume":"63","author":"Ishizu","year":"2014","journal-title":"Hypertension"},{"key":"2026012115083064800_ehf213177-bib-0029","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.jacc.2018.07.102","article-title":"Sacubitril\/valsartan averts adverse post-infarction ventricular remodeling and preserves systolic function in rabbits","volume":"72","author":"Torrado","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012115083064800_ehf213177-bib-0030","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"2026012115083064800_ehf213177-bib-0031","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/eurheartj\/ehz158","article-title":"The continuous heart failure spectrum: moving beyond an ejection fraction classification","volume":"40","author":"Triposkiadis","year":"2019","journal-title":"Eur Heart J"},{"key":"2026012115083064800_ehf213177-bib-0032","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1161\/HYPERTENSIONAHA.111.186072","article-title":"Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: heart failure causes severe lung disease","volume":"59","author":"Chen","year":"2012","journal-title":"Hypertension"},{"key":"2026012115083064800_ehf213177-bib-0033","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"2026012115083064800_ehf213177-bib-0034","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/1755-5922.12183","article-title":"Pharmacodynamic and pharmacokinetic profiles of sacubitril\/valsartan (LCZ696) in patients with heart failure and reduced ejection fraction","volume":"34","author":"Kobalava","year":"2016","journal-title":"Cardiovasc Ther"},{"key":"2026012115083064800_ehf213177-bib-0035","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ejhf.1342","article-title":"Effects of sacubitril\/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study","volume":"21","author":"Nougue","year":"2019","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13177","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13177","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/2\/918\/65927224\/eschf_8_2_918.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/2\/918\/65927224\/eschf_8_2_918.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:10:43Z","timestamp":1769026243000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/8\/2\/918\/8381989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,26]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1,26]]},"published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13177","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4]]},"published":{"date-parts":[[2021,1,26]]},"assertion":[{"value":"2020-06-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}